$PIRS
PIERIS PHARMACEUTICALS, INC. Stock $pirs

$pirs Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000158364822000065 Filed on August 04, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$5.370M	$3.698M	$10.99M
YoY Change	32.36%	12.57%	-29.71%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.949M	$4.081M	$4.379M
YoY Change	-4.43%	-3.89%	6.03%
% of Gross Profit
Research & Development	$13.59M	$11.95M	$14.07M
YoY Change	-28.24%	-24.39%	-15.07%
% of Gross Profit
Depreciation & Amortization	$767.0K	$583.0K	$845.0K
YoY Change	26.15%	-4.74%	34.13%
% of Gross Profit
Operating Expenses	$17.54M	$16.03M	$18.45M
YoY Change	-23.98%	-20.04%	-10.86%
Operating Profit	-$12.17M	-$12.33M	-$7.457M
YoY Change	-36.0%	-26.44%	47.4%
Interest Expense	$241.0K	$132.0K	-$3.000K
YoY Change	5925.0%	4300.0%	-200.0%
% of Operating Profit
Other Income/Expense, Net	$723.0K	$676.0K	$229.0K
YoY Change	6.64%	45.69%	-74.1%
Pretax Income	-$9.736M	-$10.34M	-$5.101M
YoY Change	-41.12%	-33.29%	22.33%
Income Tax
% Of Pretax Income
Net Earnings	-$9.700M	-$10.30M	-$5.100M
YoY Change	-41.21%	-33.55%	21.43%
Net Earnings / Revenue	-180.63%	-278.53%	-46.41%
Basic Earnings Per Share	-$0.13	-$0.14	-$0.07
Diluted Earnings Per Share	-$130.9K	-$0.14	-$0.07
COMMON SHARES
Basic Shares Outstanding	74.41M shares	74.13M shares	73.71M shares
Diluted Shares Outstanding		74.13M shares	73.71M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$69.82M	$80.94M	$100.3M
YoY Change	-44.16%	-32.04%	50.1%
Cash & Equivalents	$48.42M	$54.26M	$83.74M
Short-Term Investments	$21.40M	$26.68M	$16.53M
Other Short-Term Assets	$7.908M	$8.704M	$9.837M
YoY Change	32.93%	50.77%	75.66%
Inventory
Prepaid Expenses
Receivables	$829.0K	$1.264M	$1.644M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$78.56M	$90.90M	$111.7M
YoY Change	-42.93%	-28.8%	26.6%
LONG-TERM ASSETS
Property, Plant & Equipment	$15.90M	$17.43M	$18.85M
YoY Change	-18.95%	-14.45%	-8.11%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.307M	$2.358M	$2.673M
YoY Change	-55.69%	-24.5%	-16.81%
Total Long-Term Assets	$20.60M	$23.41M	$25.37M
YoY Change	-22.36%	-14.45%	-7.81%
TOTAL ASSETS
Total Short-Term Assets	$78.56M	$90.90M	$111.7M
Total Long-Term Assets	$20.60M	$23.41M	$25.37M
Total Assets	$99.16M	$114.3M	$137.1M
YoY Change	-39.6%	-26.27%	18.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.641M	$1.898M	$4.496M
YoY Change	2.22%	-17.84%	29.68%
Accrued Expenses	$11.38M	$10.18M	$11.86M
YoY Change	-42.18%	-36.73%	24.01%
Deferred Revenue	$18.50M	$22.86M	$20.91M
YoY Change	-30.06%	-10.47%	21.33%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$33.52M	$35.55M	$39.48M
YoY Change	-32.55%	-19.08%	30.46%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$29.88M	$34.40M	$44.18M
YoY Change
Total Long-Term Liabilities	$29.88M	$34.40M	$44.18M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$33.52M	$35.55M	$39.48M
Total Long-Term Liabilities	$29.88M	$34.40M	$44.18M
Total Liabilities	$63.40M	$69.94M	$83.67M
YoY Change	-42.54%	-35.42%	7.89%
SHAREHOLDERS EQUITY
Retained Earnings	-$282.3M	-$272.6M	-$262.2M
YoY Change	14.01%	17.96%	21.61%
Common Stock	$74.00K	$316.3M	$314.7M
YoY Change	-99.98%	13.96%	24.1%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$35.77M	$44.37M	$53.45M
YoY Change
Total Liabilities & Shareholders Equity	$99.16M	$114.3M	$137.1M
YoY Change	-39.6%	-26.27%	18.42%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$9.700M	-$10.30M	-$5.100M
YoY Change	-41.21%	-33.55%	21.43%
Depreciation, Depletion And Amortization	$767.0K	$583.0K	$845.0K
YoY Change	26.15%	-4.74%	34.13%
Cash From Operating Activities	-$8.778M	-$15.58M	-$22.64M
YoY Change	-39.4%	-152.09%	86.55%
INVESTING ACTIVITIES
Capital Expenditures	-$34.00K	-$629.0K	$389.0K
YoY Change	-90.29%	177.09%	1289.29%
Acquisitions
YoY Change
Other Investing Activities	$5.504M	-$10.24M	-$16.56M
YoY Change
Cash From Investing Activities	$5.470M	-$10.86M	-$16.95M
YoY Change	-1662.86%	4686.34%	60428.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$6.473M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	282.0K	281.0K	$6.558M
YoY Change	-98.71%	-98.76%	-32.34%
NET CHANGE
Cash From Operating Activities	-8.778M	-15.58M	-$22.64M
Cash From Investing Activities	5.470M	-10.86M	-$16.95M
Cash From Financing Activities	282.0K	281.0K	$6.558M
Net Change In Cash	-3.026M	-26.16M	-$34.03M
YoY Change	-142.73%	-150.02%	844.93%
FREE CASH FLOW
Cash From Operating Activities	-$8.778M	-$15.58M	-$22.64M
Capital Expenditures	-$34.00K	-$629.0K	$389.0K
Free Cash Flow	-$8.744M	-$14.95M	-$23.03M
YoY Change	-38.13%	-149.61%	89.31%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001583648
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q2	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccountsPayableAndOtherAccruedLiabilitiesCurrent
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccountsPayableAndOtherAccruedLiabilitiesCurrent
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-37471
	dei	Entity Registrant Name EntityRegistrantName	PIERIS PHARMACEUTICALS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	30-0784346
	dei	Entity Address Address Line1 EntityAddressAddressLine1	255 State Street,
	dei	Entity Address Address Line2 EntityAddressAddressLine2	9th Floor
	dei	Entity Address City Or Town EntityAddressCityOrTown	Boston,
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Country EntityAddressCountry	US
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02109
	dei	City Area Code CityAreaCode	857
	dei	Local Phone Number LocalPhoneNumber	246-8998
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
	dei	Trading Symbol TradingSymbol	PIRS
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	74406253	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54257000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	117764000	usd
CY2022Q2	us-gaap	Short Term Investments ShortTermInvestments	26679000	usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	0	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1264000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3313000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8704000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6548000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	90904000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	127625000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17430000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19122000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3617000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3909000	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2358000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2904000	usd
CY2022Q2	us-gaap	Assets Assets	114309000	usd
CY2021Q4	us-gaap	Assets Assets	153560000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1898000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8609000	usd
CY2022Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	10785000	usd
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	16836000	usd
CY2022Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	22863000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	25116000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	35546000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	50561000	usd
CY2022Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	22063000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	38403000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	12335000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	13841000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	69944000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	102805000	usd
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	74000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	72000	usd
CY2022Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	316249000	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	306998000	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	625000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	829000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-272583000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-257144000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	44365000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	50755000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	114309000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	153560000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3468000	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2540000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	14647000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	17406000	usd
CY2022Q2	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	230000	usd
CY2021Q2	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	745000	usd
	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	39000	usd
	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	1512000	usd
CY2022Q2	us-gaap	Revenues Revenues	3698000	usd
CY2021Q2	us-gaap	Revenues Revenues	3285000	usd
	us-gaap	Revenues Revenues	14686000	usd
	us-gaap	Revenues Revenues	18918000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11947000	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15800000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26013000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	32362000	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4081000	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4246000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8460000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8376000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	16028000	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	20046000	usd
	us-gaap	Operating Expenses OperatingExpenses	34473000	usd
	us-gaap	Operating Expenses OperatingExpenses	40738000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-12330000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-16761000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-19787000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-21820000	usd
CY2022Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	132000	usd
CY2021Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	3000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	129000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	6000	usd
CY2022Q2	pirs	Revenue Not From Contract With Customer Grant Income RevenueNotFromContractWithCustomerGrantIncome	1184000	usd
CY2021Q2	pirs	Revenue Not From Contract With Customer Grant Income RevenueNotFromContractWithCustomerGrantIncome	796000	usd
	pirs	Revenue Not From Contract With Customer Grant Income RevenueNotFromContractWithCustomerGrantIncome	3314000	usd
	pirs	Revenue Not From Contract With Customer Grant Income RevenueNotFromContractWithCustomerGrantIncome	796000	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	676000	usd
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	464000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	905000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1348000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-10338000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-15498000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-15439000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-19670000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-499000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	40000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-356000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	529000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	171000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	152000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10666000	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15458000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15643000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19141000	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.25
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.25
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.33
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.33
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74125000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	74125000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61905000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61905000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	73919000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	73919000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	59116000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	59116000	shares
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	38236000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-15498000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	40000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1326000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	272000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	96000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	837000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	0	usd
CY2021Q2	pirs	Stock Issued During Period Value Conversion Of Preferred Stock StockIssuedDuringPeriodValueConversionOfPreferredStock	0	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	46721000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	53450000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-10338000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-499000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	171000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1301000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	10000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	104000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	44365000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	31027000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-19670000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	529000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2525000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	292000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	96000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	837000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	0	usd
	pirs	Stock Issued During Period Value Conversion Of Preferred Stock StockIssuedDuringPeriodValueConversionOfPreferredStock	0	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	46721000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	50755000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-15439000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-356000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	152000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2479000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	95000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	104000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	44365000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-15439000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-19670000	usd
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	1428000	usd
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	1242000	usd
	pirs	Operating Lease Right Of Use Asset Accretion OperatingLeaseRightOfUseAssetAccretion	5000	usd
	pirs	Operating Lease Right Of Use Asset Accretion OperatingLeaseRightOfUseAssetAccretion	48000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2479000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2525000	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-40000	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-214000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	14000	usd
	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	26938000	usd
	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	-33733000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-38221000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	17768000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1018000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	257000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	4850000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	0	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	31645000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-19700000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-27813000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-257000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	95000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	292000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	837000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	104000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	96000	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	18913000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	300000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6640000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	12172000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6839000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	32310000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-272600000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-4312000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1160000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-63507000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	48661000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	117764000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	70436000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	54257000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	119097000	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	152000	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	usd
	pirs	Property And Equipment Included In Accounts Payable PropertyAndEquipmentIncludedInAccountsPayable	15000	usd
	pirs	Property And Equipment Included In Accounts Payable PropertyAndEquipmentIncludedInAccountsPayable	0	usd
CY2022Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	80900000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-10300000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-15500000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-15400000	usd
	us-gaap	Use Of Estimates UseOfEstimates	The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates are used for, but are not limited to, revenue recognition; deferred tax assets, deferred tax liabilities and valuation allowances; determination of the incremental borrowing rate to calculate right-of-use assets and lease liabilities; beneficial conversion features; fair value of stock options, preferred stock, and warrants; and prepaid and accrued clinical trial expenses. Management evaluates its estimates on an ongoing basis. Actual results and outcomes could differ materially from management’s estimates, judgments and assumptions.
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	The Company has no financial instruments with off-balance sheet risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements. Financial instruments that subject Pieris to concentrations of credit risk include cash and cash equivalents, investments, and accounts receivable. The Company’s cash, cash equivalents, and investments are held in accounts with financial institutions that management believes are creditworthy. The Company’s investment policy includes guidelines on the quality of the institutions and financial instruments and defines allowable investments that the Company believes minimize the exposure to concentration of credit risk. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. Accounts receivable primarily consist of amounts due under strategic partnership and other license agreements with major multi-national pharmaceutical companies for which the Company does not obtain collateral.
CY2022Q2	us-gaap	Revenues Revenues	3698000	usd
CY2021Q2	us-gaap	Revenues Revenues	3285000	usd
	us-gaap	Revenues Revenues	14686000	usd
	us-gaap	Revenues Revenues	18918000	usd
CY2017Q2	pirs	Number Of Technology Licenses NumberOfTechnologyLicenses	5	lease_agreement
CY2022Q2	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	usd
CY2022Q2	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	3700000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	14300000	usd
CY2021Q2	us-gaap	Grants Receivable GrantsReceivable	14200000	eur
CY2021Q2	us-gaap	Grants Receivable GrantsReceivable	17000000	usd
CY2022Q2	pirs	Cash Equivalents And Investments CashEquivalentsAndInvestments	51867000	usd
CY2021Q4	pirs	Cash Equivalents And Investments CashEquivalentsAndInvestments	56885000	usd
CY2022Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	26527000	usd
CY2022Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	191000	usd
CY2022Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	39000	usd
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	26679000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	25675000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	26839000	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8245000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7717000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17430000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19122000	usd
CY2022Q2	pirs	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	4457000	usd
CY2021Q4	pirs	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	5682000	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2462000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3581000	usd
CY2022Q2	pirs	Accrued License Obligations Current AccruedLicenseObligationsCurrent	1338000	usd
CY2021Q4	pirs	Accrued License Obligations Current AccruedLicenseObligationsCurrent	1541000	usd
CY2022Q2	pirs	Accrued Accounts Payable Current AccruedAccountsPayableCurrent	1004000	usd
CY2021Q4	pirs	Accrued Accounts Payable Current AccruedAccountsPayableCurrent	2980000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	914000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1049000	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	610000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	393000	usd
CY2022Q2	pirs	Accrued Collaboration Costs Current AccruedCollaborationCostsCurrent	0	usd
CY2021Q4	pirs	Accrued Collaboration Costs Current AccruedCollaborationCostsCurrent	1610000	usd
CY2022Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	10785000	usd
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	16836000	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	39600000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	36500000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	74257587	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	74257587	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	72222661	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	72222661	shares
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	15617	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	15617	shares
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	15617	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	15617	shares
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	331000	usd
CY2021Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	379000	usd
CY2022Q2	us-gaap	Variable Lease Cost VariableLeaseCost	165000	usd
CY2021Q2	us-gaap	Variable Lease Cost VariableLeaseCost	181000	usd
CY2022Q2	us-gaap	Lease Cost LeaseCost	496000	usd
CY2021Q2	us-gaap	Lease Cost LeaseCost	560000	usd
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.105
CY2022Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	600000	usd
CY2021Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	600000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	1100000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	1300000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1152000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2059000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2059000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2059000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2059000	usd
CY2022Q2	pirs	Lessee Operating Lease Liability To Be Paid Due After Year Four LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour	11494000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	20882000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	7632000	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	13250000	usd

Files In Submission

Name	View Source	Status
0001583648-22-000065-index-headers.html	Edgar Link	pending
0001583648-22-000065-index.html	Edgar Link	pending
0001583648-22-000065.txt	Edgar Link	pending
0001583648-22-000065-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pirs-20220630.htm	Edgar Link	pending
pirs-20220630.xsd	Edgar Link	pending
pirs-20220630_cal.xml	Edgar Link	unprocessable
pirs-20220630_def.xml	Edgar Link	unprocessable
pirs-20220630_htm.xml	Edgar Link	completed
pirs-20220630_lab.xml	Edgar Link	unprocessable
pirs-20220630_pre.xml	Edgar Link	unprocessable
pirs063022_exx102.htm	Edgar Link	pending
pirs063022_exx102001.jpg	Edgar Link	pending
pirs063022_exx102002.jpg	Edgar Link	pending
pirs063022_exx102003.jpg	Edgar Link	pending
pirs063022_exx103.htm	Edgar Link	pending
pirs063022_exx103001.jpg	Edgar Link	pending
pirs063022_exx103002.jpg	Edgar Link	pending
pirs063022_exx103003.jpg	Edgar Link	pending
pirs6-30x22ex311.htm	Edgar Link	pending
pirs6-30x22ex312.htm	Edgar Link	pending
pirs6-30x22ex321.htm	Edgar Link	pending
pirs6-30x22ex322.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PIRS
PIERIS PHARMACEUTICALS, INC. Stock $pirs

2022 Q3 Form 10-Q Financial Statement

#000158364822000065 Filed on August 04, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PIRS PIERIS PHARMACEUTICALS, INC. Stock $pirs

2022 Q3 Form 10-Q Financial Statement

#000158364822000065 Filed on August 04, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PIRS
PIERIS PHARMACEUTICALS, INC. Stock $pirs